Overview


Neuropathic pain is a chronic pain condition caused owing to infection, trauma and other such dysfunctional systems in the nerves. Primary neuropathic pain syndromes include postherpetic neuralgia, painful neuropathy, painful traumatic mononeuropathy, central pain syndromes, complex regional pain syndrome and postsurgical pain syndromes. Anticonvulsants, antidepressants like tricyclic antidepressants and anaesthetics are generally prescribed for neuropathic pain.

Furthermore, antidepressants like nortriptyline and amitriptyline are primarily used for managing neuropathic pain. Additionally, the growing prevalence of chronic diseases like diabetes and cancer shall bolster the neuropathic pain management market growth. However, a dearth of awareness pertaining to the implementation of the procedure in underdeveloped regions shall impede the proliferation of the market. Conversely, rise in the number of pain centres shall boost the augmentation of the market.

  • Baxter International Inc.
  • Biogen Inc
  • Bristol-Myers Squibb and Company
  • Assertio Therapeutics Inc.
  • Eli Lily and Company
  • GlaxoSmithKline PLC
  • Johnson and Johnson Services Inc.
  • Pfizer Inc.
  • Sanofi S.A.
  • MerckCo.
  • Teva Pharmaceutical Industries Ltd.

(Note: The list of the major players will be updated with the latest market scenario and trends)

By Drug Class

  • Gabapentinoids
  • Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs)
  • Tricyclic Antidepressants
  • Combination Drugs
  • Others

By Route of Administration

  • Oral
  • Topical
  • Transdermal

By Indications

  • Diabetic Neuropathy
  • Trigeminal Neuralgia
  • Post-Herpetic Neuralgia
  • Chemotherapy-Induced Peripheral Neuropathy
  • Other Indications

By Distribution Channel

  • Hospital Pharmacies
  • Retail/ Drug Stores
  • Online Pharmacies

By Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa

The market is categorised into drug class, indication, distribution channel and region. The drug class segment is classified into tricyclic antidepressants, anticonvulsants, SNRIs, capsaicin cream, local anaesthesia, opioids, steroids and others. The tricyclic antidepressants segment is predicted to hold the largest neuropathic pain management market share during the forecasted timeframe. The indication segment is fragmented into diabetic neuropathy, trigeminal neuralgia, post-herpetic neuralgia, chemotherapy-induced peripheral neuropathy and others. The distribution channel segment is diversified into retail pharmacies, hospital pharmacies and online pharmacies. The hospital pharmacies segment is anticipated to lead the market owing to growing investments for hospitals in developed and underdeveloped nations.

The North America region is expected to dominate the market and this can be credited to increased disposable income, rising geriatric population, a strong presence of key market players in the region.

  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants

  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth

  • To provide with an exhaustive analysis on the global Neuropathic Pain Management Market By Drug Class, By Route Of Administration, By Indications, By Distribution Channel and By Region
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions (along with countries)— North America, Europe, Asia Pacific, Latin America and Middle East and Africa
  • To record, evaluate and analyze competitive landscape mapping- product launches, technological advancements, mergers, and expansions

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1. Years Considered for the Study
         3.2. Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1. Secondary Data
          1.1.1. Key Data from Secondary Sources
         1.2. Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Neuropathic Pain Management Market Variables, Trends and Scope
    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Technology Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Neuropathic Pain Management Market Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Neuropathic Pain Management Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Technology Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Technology Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Neuropathic Pain Management Market, By Drug Class Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Gabapentinoids
        2. Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs)
        3. Tricyclic Antidepressants
        4. Combination Drugs
        5. Others

  • 8.   Neuropathic Pain Management Market, By Route of Administration Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Oral
        2. Topical
        3. Transdermal

  • 9.   Neuropathic Pain Management Market, By Indications Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Diabetic Neuropathy
        2. Trigeminal Neuralgia
        3. Post-Herpetic Neuralgia
        4. Chemotherapy-Induced Peripheral Neuropathy
        5. Other Indications

  • 10.   Neuropathic Pain Management Market, By Distribution Channel Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Hospital Pharmacies
        2. Retail/ Drug Stores
        3. Online Pharmacies

  • 11.   North America Neuropathic Pain Management Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 12.   Latin America Neuropathic Pain Management Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2023-2031

  • 13.   Europe Neuropathic Pain Management Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Germany
          2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 14.   Asia Pacific Neuropathic Pain Management Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031

  • 15.   Middle East and Africa Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. GCC
         2.2. Israel
         2.3. South Africa
         2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 16.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 17.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    •   1. Baxter International Inc.
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. Biogen Inc
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. Bristol-Myers Squibb and Company
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. Assertio Therapeutics Inc.
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. Eli Lily and Company
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. GlaxoSmithKline PLC
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. Johnson and Johnson Services Inc.
         7.1. Company Overview
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. Pfizer Inc.
         8.1. Company Overview
         8.2. Product Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
        9. Sanofi S.A.
         9.1. Company Overview
         9.2. Product Portfolio
         9.3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview
        10. MerckCo.
         10.1. Company Overview
         10.2. Product Portfolio
         10.3. SWOT Analysis
         10.4. Financial Overview
         10.5. Strategic Overview
        11. Teva Pharmaceutical Industries Ltd.
         11.1. Company Overview
         11.2. Product Portfolio
         11.3. SWOT Analysis
         11.4. Financial Overview
         11.5. Strategic Overview

  • 18.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the healthcare regulations initiated by
                   administrations
        5. The overall economic slowdown of the developing and developed nations

  • 19.   FutureWise SME Key Takeaway Points for Client
Partner

Our Clients